Morgan & Morgan Reminds Investors That a Class Action

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Morgan & Morgan Reminds Investors That a Class Action Lawsuit Has Been Filed Against Arrowhead Research Corporation -- ARWR

NEW YORK, Oct. 23, 2014 (GLOBE NEWSWIRE) -- Morgan & Morgan announces that a securities class action has been commenced in the United States District Court for the Central District of California on behalf of purchasers of common stock of Arrowhead Research Corporation ("Arrowhead") (Nasdaq: ARWR ) during the period of August 12, 2014 through October 8, 2014, inclusive (the "Class Period").

If you purchased Arrowhead stock during the Class Period, you may, no later than December 9, 2014, request that the Court appoint you lead plaintiff of the proposed class. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

If you want more information about the Arrowhead Research Corporation Securities Class Action please contact Morgan & Morgan at 1-800-732-5200 or email info@morgansecuritieslaw.com.

The class action alleges that the Company and certain of its officers and/or directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint alleges that Arrowhead materially misstated clinical trial information from its experimental hepatitis B therapy ARC-520 by falsely suggesting that the Company's therapy was more effective than it actually was.

On October 8, 2014, Arrowhead released disappointing data from its ARC-520 therapy. On that same day, an article published on TheStreet.com reported that Arrowhead CEO Chris Anzalone and his team knew for months that ARC-520 dosed at 1 mg/kg and 2 mg/kg yielded only 0.2-log and 0.3-log reductions in hepatitis B viral load. Arrowhead executives had led investors to believe that ARC-520 was more potent and achieved substantially larger viral load reductions in the range of 0.7 log or higher. On the news of October 8 th , shares of Arrowhead plummeted by $5.48 per share, or over 43%, to close at $7.03 per share.

About Morgan & Morgan

Morgan & Morgan is one of the nation's largest 200 law firms. In addition to securities fraud , the firm also practices in the areas of antitrust, personal injury, consumer protection, wage and hour, and product liability.  All of the Firm's legal endeavors are rooted in its core mission: provide investor and consumer protection and always fight "for the people." 

Attorney advertising. Prior results do not guarantee a similar outcome.

Morgan & Morgan Peter Safirstein, Esq. 28 West 44th Street Suite 2001 New York, NY 10036 1-800-732-5200

Scroll down for more posts ▼

Top 10 Most Recent News Articles

APEC's Shared-Prosperity Message Needs More Detail

Updated Category News Views 13

Geese make handsome symbols, but markets cannot underwrite a metaphor. The Nov. 18, 2026 report from Xinhua News Agency looks back to remarks Chinese President Xi Jinping made 12 years ago, when he used swan geese to urge APEC economies toward greater cooperation and a new collective flight. Its present-day message is plainly hopeful: the APEC family is moving across the...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 85

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 130

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 53

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 28

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 19

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push

Updated Category News Views 35

A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 196

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into 1st Colonial Bancorp's Sale

Updated Category News Views 256

Exploring the Sale of 1st Colonial Bancorp, Inc. In a significant development for shareholders, the M&A Class Action Firm has initiated an investigation into 1st Colonial Bancorp, Inc. (OTCMKTS: FCOB) regarding its proposed acquisition by Mid Penn Bancorp, Inc. This merger, which has garnered attention in the financial community, raises important questions about the...

Continue Reading
American Tungsten Pursues $10 Million Investment Opportunity

Updated Category News Views 181

American Tungsten Seeks $10 Million Through Private Placement American Tungsten Corp. (CSE:TUNG) (OTCQB:TUNGF) has announced an exciting initiative to raise up to $10 million through a non-brokered private placement, aiming to issue over 2.8 million common shares priced at $3.50 each. This move reflects the heightened demand for critical metals and underscores the...

Continue Reading
Arcadia Biosciences Surpasses Revenue Goals in Q3 2025

Updated Category News Views 188

Arcadia Biosciences Reports Strong Financial Results Arcadia Biosciences, Inc. (NASDAQ: RKDA), a leader in the wellness products sector, recently revealed its financial and operational highlights for the third quarter of 2025. This report showcases the continued growth and resilience of the company amid various market challenges. Year-to-Date Performance As of the third...

Continue Reading
Artificial Superintelligence Alliance Sees Strong Price Gains

Updated Category News Views 71

Overview of Recent Price Movements In the past 24 hours, the price of Artificial Superintelligence Alliance has seen an impressive increase of 5.78%, reaching $1.35. This surge is part of a broader upward trend throughout the week, where it has lifted by 3.0% from $1.33. It's worth noting that the coin's all-time high is recorded at $3.45. Analyzing Volatility and Trends...

Continue Reading
How Bitcoin Boosted Robert Kiyosaki's Wealth Journey

Updated Category News Views 311

Robert Kiyosaki's Insights on Bitcoin Robert Kiyosaki, known for his influential book "Rich Dad Poor Dad," recently shared his experiences and beliefs about Bitcoin, a digital asset he credits for significantly enhancing his wealth. He has gained notoriety as a financial guru, and his comments on Bitcoin have sparked considerable interest in the cryptocurrency market....

Continue Reading